Skip to main content
padlock icon - secure page this page is secure

Thymidylate Synthase Gene in Pharmacogenetics

Buy Article:

$68.00 + tax (Refund Policy)

Thymidylate synthase (TS) is the target for widely used anticancer agent 5-fluorouracil (5-FU) and a number of other TS inhibitors are now either in clinical use or under development. The TS gene has a variable number of tandem repeat (VNTR) sequence, mainly 2 repeats (2R) and 3 repeats (3R), which are promising candidates for prediction of the effectiveness and adverse drug reactions of TS inhibitors. It has been demonstrated both in vitro and in vivo that the 3R allele is associated with higher levels of expression of TS mRNA or TS protein as compared to the 2R allele. This association provides a plausible explanation for the clinical observations that homozygous 3R / 3R patients have a lower probability of response and less frequent adverse drug effects of 5-FU-based chemotherapy than those homozygous for 2R / 2R or heterozygous for 2R / 3R. However, some studies found neither an association between TS VNTR genotype and TS expression nor any relationship between the genotype and clinical outcome of 5-FU-based chemotherapy. Recent studies suggested that other polymorphisms, gene alterations of TS and cancer phenotypes relevant to TS VNTR polymorphism may be involved in the outcome of 5-FU-based chemotherapy. These variables include loss of heterozygosity at the TS locus, novel single nucleotide polymorphism of TS, TS 1494del6 polymorphism and methylenetetrahydrofolate reductase polymorphism. Future clinical trials should collect information regarding these genetic variables to evaluate their predictive value and realize tailored chemotherapy in 5-FU-based chemotherapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anti-metabolite; cancer chemotherapy; gene polymorphism; pharmacogenetics; thymidylate synthase

Document Type: Review Article

Affiliations: Department of Surgery, Kanazawa University School of Medicine, 13-1 Takaramachi, Kanazawa 920-8641, Japan.

Publication date: June 1, 2004

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more